Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,846 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,846 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02040142 | HIPEC for Peritoneal Carcinomatosis | completed | Phase 2 | 51 | Albert Einstein College of MedicineOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT00807911 | Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer | completed | Phase 2 | 322 | Asan Medical CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT02096354 |
| A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer(ROCKET) |
| completed |
| Phase 2 |
| 62 |
| EpicentRx, Inc.INDUSTRY |
| 1 |
| Oct 15, 2024 |
| clinicaltrials |
| NCT03435107 | Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer | completed | Phase 2 | 33 | Asan Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT01839877 | Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study | completed | Phase 2 | 58 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03475004 | Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | completed | Phase 2 | 53 | University of Colorado, DenverOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT06597903 | A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution | completed | Phase 2 | 36 | NorgineINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03800602 | Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer | completed | Phase 2 | 29 | Emory UniversityOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT02466009 | Regorafenib in Metastatic Colorectal Cancer | completed | Phase 2 | 27 | University of RochesterOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT02860546 | A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | completed | Phase 2 | 18 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 3, 2024 | clinicaltrials |
| NCT03263429 | Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer | completed | Phase 1 / Phase 2 | 29 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT02705300 | Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer | completed | Phase 2 | 70 | Vejle HospitalOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02873195 | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 133 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT03981614 | Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | completed | Phase 2 | 102 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05086627 | Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer | completed | Phase 2 | 118 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT02743221 | A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy(TASCO1) | completed | Phase 2 | 154 | Institut de Recherches Internationales ServierOTHER | 12 | Aug 20, 2024 | clinicaltrials |
| NCT05662527 | Response to Immunotherapy in MMR-deficient Localized Colon Cancer(RESET-C) | completed | Phase 2 | 85 | Camilla QvortrupOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT00788957 | Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | completed | Phase 1 / Phase 2 | 177 | NantBioScience, Inc.INDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT03274882 | Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies | completed | Phase 2 | 26 | Institut de Recherches Internationales ServierOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT00891930 | Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab | completed | Phase 2 | 74 | NantBioScience, Inc.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT02384759 | Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers(FOLFA) | completed | Phase 2 | 117 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06454071 | Immunologic Changes and Recovery-related Factors in Elderly Colon Cancer Patients | completed | Phase 2 | 75 | Soonchunhyang University HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT02834052 | Pembrolizumab + Poly-ICLC in MRP Colon Cancer | completed | Phase 1 / Phase 2 | 42 | Asha NayakOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT03144804 | A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)(MODUL) | completed | Phase 2 | 1,044 | Hoffmann-La RocheINDUSTRY | 23 | May 6, 2024 | clinicaltrials |
| NCT04216251 | PRevention Using EPA Against coloREctal Cancer(PREPARE) | completed | Phase 1 / Phase 2 | 81 | Massachusetts General HospitalOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT03146962 | High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies | completed | Phase 2 | 61 | Weill Medical College of Cornell UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04205955 | Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors | completed | Phase 2 | 95 | SWOG Cancer Research NetworkNETWORK | 2 | May 1, 2024 | clinicaltrials |
| NCT04124601 | Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer(CHINOREC) | completed | Phase 2 | 80 | Johannes Laengle, MD, PhDOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT04271813 | Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) | completed | Phase 2 | 30 | Shanghai Changzheng HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT00321828 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 90 | NSABP Foundation IncNETWORK | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT00407654 | VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03530267 | Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer(ELDERLY) | completed | Phase 2 | 124 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03559543 | Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma | completed | Phase 2 | 40 | Catalysis SLINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05468892 | Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial(VELO) | completed | Phase 2 | 68 | University of Campania Luigi VanvitelliOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03698461 | Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab(CLIMB) | completed | Phase 2 | 20 | Asan Medical CenterOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02399410 | Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis | completed | Phase 2 | 60 | University Hospital, GhentOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02316340 | Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | completed | Phase 2 | 42 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT02870920 | Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer | completed | Phase 2 | 180 | Canadian Cancer Trials GroupNETWORK | 1 | Dec 8, 2023 | clinicaltrials |
| NCT03485027 | Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer | completed | Phase 2 | 43 | Fudan UniversityOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02195011 | Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases | completed | Phase 2 | 26 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02363374 | Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer(CAOAROAIO-12) | completed | Phase 2 | 311 | Prof. Dr. med. Claus RödelOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT03414983 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread(CheckMate 9X8) | completed | Phase 2 / Phase 3 | 196 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 24, 2024source: clinicaltrials